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LiverMethylmercury (MeHg) is an ubiquitous environmental pollutant which is transported into the
mammalian cells when present as the methylmercury-cysteine conjugate (MeHg–Cys). With special
emphasis on hepatic cells, due to their particular propensity to accumulate an appreciable amount of Hg
after exposure to MeHg, this study was performed to evaluate the effects of methionine (Met) on Hg
uptake, reactive species (RS) formation, oxygen consumption and mitochondrial function/cellular
viability in both liver slices and mitochondria isolated from these slices, after exposure to MeHg or
the MeHg–Cys complex. The liver slices were pre-treated with Met (250 μM) 15 min before being
exposed to MeHg (25 μM) or MeHg–Cys (25 μM each) for 30 min at 37 °C. The treatment with MeHg
caused a signiﬁcant increase in the Hg concentration in both liver slices and mitochondria isolated from
liver slices. Moreover, the Hg uptake was higher in the group exposed to the MeHg–Cys complex. In the
DCF (dichloroﬂuorescein) assay, the exposure to MeHg and MeHg–Cys produced a signiﬁcant increase in
DFC reactive species (DFC-RS) formation only in the mitochondria isolated from liver slices. As observed
with Hg uptake, DFC-RS levels were signiﬁcantly higher in the mitochondria treated with the MeHg–Cys
complex compared to MeHg alone. MeHg exposure also caused a marked decrease in the oxygen
consumption of liver slices when compared to the control group, and this effect was more pronounced
in the liver slices treated with the MeHg–Cys complex. Similarly, the loss of mitochondrial activity/cell
viability was greater in liver slices exposed to the MeHg–Cys complex when compared to slices treated
only with MeHg. In all studied parameters, Met pre-treatment was effective in preventing the MeHg-
and/or MeHg–Cys-induced toxicity in both liver slices and mitochondria. Part of the protection afforded
by Met against MeHg may be related to a direct interaction with MeHg or to the competition of Met
with the complex formed between MeHg and endogenous cysteine. In summary, our results show that
Met pre-treatment produces pronounced protection against the toxic effects induced by MeHg and/or
the MeHg–Cys complex on mitochondrial function and cell viability. Consequently, this amino acid offers
considerable promise as a potential agent for treating acute MeHg exposure.Santa Maria, Departamento de
nta Maria, RS, Brazil. Fax: +55
ha), nvbarbosa@yahoo.com.br
vier OA license.© 2011 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Exposure to methylmercury (MeHg), the most toxic form of
mercury (Hg) in the environment, is well recognized as the cause of a
series of cellular disorders in several systems, especially in the centralnervous system (CNS) (Choi 1991; Sakamoto et al., 1998; Clarkson
et al., 2003; Sakaue et al., 2006). However, the exact molecular
mechanisms underlyingMeHg-induced toxicity in the developing and
adult CNS, as well as in other tissues, remain unclear. The methyl
mercuric ion (CH3Hg+) does not exist in biological systems as a free,
unbound cation (Hughes, 1957), but rather, is found conjugated to
thiol-containing biomolecules, such as glutathione (GSH), cysteine
(Cys) and homocysteine (Hcy) (Clarkson, 1993). Thus, many of the
mechanisms proposed to explain the rapid diffusion of MeHg across
membranes and, consequently, the cellular damage induced by MeHg
is largely based upon its high afﬁnity for −SH groups. Corroborating
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and cellular uptake of MeHg are signiﬁcantly increased when it is
present as Cys– or Homocysteine–MeHg conjugates (Ballatori, 2002;
Roos et al., 2010). Additionally, experimental evidence supports
the idea that the neutral amino acid transport system L is a signiﬁcant
route for MeHg–Cys transmembrane movement (Yin et al., 2008;
Roos et al., 2010), since MeHg–Cys complexes are thought to mimic
structurally methionine (Met), a substrate for amino acid carriers
such as the L-type large neutral amino acid transporters (LATs). The
major LATs subtypes (LAT1, LAT2 and LAT3) are widely expressed in
organs and tissues of the kidney, placenta, brain and intestinal wall
(Palacín et al., 1998; Kanai and Endou, 2001). In the liver, amino acid
transporters with system L transport activity have been identiﬁed
mainly in human hepatoblastoma cell line HepG2 (Sarkar et al., 1999).
However, the physiological function as well as the precise subcellular
localization of these transporters in normal hepatic cells has yet to be
determined (Bode, 2001; Babu et al., 2003; Fukuhara et al., 2007;
Wagner et al., 2010).
A number of particular cellular mechanisms and molecules are
the primary targets of MeHg cytotoxicity. Disruption of calcium
homeostasis and free radicals generation are among the detri-
mental effects associated with MeHg-induced toxicity (Limke et
al., 2003; Ikeda et al., 1999). In this scenario, mitochondria play a
crucial role, as these organelles can act as a buffer against
cytosolic calcium and can mediate (RS) formation in cells
(Norenberg and Rao, 2007; Chacko et al., 2009). It has been
shown that mitochondrial dysfunctions induced by MeHg include
the failure of energy metabolism, the disruption of calcium
homeostasis and the dissipation of the mitochondrial membrane
potential, effects which lead to a mitochondrial burst of reactive
oxygen species (ROS) production (Kim and Sharma 2003; Kang et
al., 2006; Dreiem and Seegal, 2007). ROS are important mediators
of damage to cell structures, including lipids and membranes, as
well as proteins and nucleic acids (Poli et al., 2004). The
detrimental effects of ROS are balanced by the antioxidant action
of non-enzymatic antioxidants in addition to antioxidant enzymes
(Poli et al., 2004). However, in vivo and in vitro experimental
observations have shown that the toxic effects of MeHg are
accompanied by a signiﬁcant deﬁcit of antioxidant defenses, such
as the depletion of GSH and the inhibition of GSH peroxidase
activity (Farina et al., 2004; Chang and Tsai, 2008; Stringari et al.,
2008; Farina et al., 2009). Thus, oxidative stress has been
implicated in a number of events involved in MeHg-induced
cytotoxicity (Roos et al., 2009).
Based on the evidence presented above, it is reasonable to
assume that Met, acting as competitive inhibitor of MeHg–Cys
transport through system L could prevent or reduce MeHg-induced
cytotoxicity. To date, there have been no studies on the efﬁcacy of
Met to attenuate mitochondrial MeHg uptake and mitochondrial
function. The experimental model employed, namely hepatic cells,
possess a particular propensity to accumulate appreciable quanti-
ties of Hg after exposure to MeHg (de Freitas et al., 2009).
Speciﬁcally, we have examined, for the ﬁrst time, the effects of
Met pre-treatment on Hg uptake, RS formation, oxygen consump-
tion and cellular viability in both liver slices and mitochondria
isolated from these slices, after exposure to MeHg or the MeHg–
Cys complex.
Materials and experimental procedures
Chemicals. MeHgCl and L-Cysteine chloride were obtained from
Aldrich (St. Louis, MO). All other chemicals were of analytical reagent
grade and were purchased from Merck (Rio de Janeiro, Brazil).
Animals. Adult male Wistar rats from our own breeding colony
(200–250 g) were maintained in Plexiglas cages with food andwater ad libitum, in a temperature-controlled room (22–25 °C) and
on a 12 h-light/dark cycle with lights on at 7:00 a.m. Animals
were handled and treated according to the guidelines set forth by
the Committee on Care and Use of Experimental Animal Resources
of the Federal University of Santa Maria, Brazil.
Preparation of liver slices. Animals were killed by decapitation, and
thewhole liver was quickly removed and placed on ice. Afterward, the
liver was cut into transverse slices 300 μm thick using a McIlwain
tissue chopper (Campbell Instruments; The Mickle Laboratory
Engineering Co). The slices were placed in Krebs–Ringer buffer
(10 mM D-glucose, 129 mM NaCl, 1.25 mM NaHPO4, 22 mM
NaHCO3, KCl 3 mM, CaCl2 1.8 mM, MgSO4 1.8 mM, Hepes 5 mM, pH
7.4), which was previously bubbled with O2 95% and CO2 5% for
30 min. Sixty slices (per group) were carefully selected, weighted
(30±2 μg each) and randomly placed in buffer (2 mL) for the
respective treatments. In the ﬁnal step of each experiment the total
protein content was determined (Peterson, 1977).
Treatment of liver slices. The slices were subdivided to the following
groups: (1) control; (2) MeHg (25 μM); (3) Cysteine (25 μM); (4)
MeHg–Cys complex (25 μM each); (5) Methionine (250 μM); (6) Met
(250 μM)+MeHg (25 μM); and (7) Met (250 μM)+MeHg–Cys
complex (25 μM each). The slices were exposed to the different
treatments for 30 min at 37 °C, in the presence of O2 (95%) and CO2
(5%). The molar ratio of cysteine to MeHg was 1, and the
stoicheometric reaction between cysteine and MeHg was conﬁrmed
by Ellman's reagent (Ellman, 1959). The Methionine groups (250 μM)
were pre-treated for 15 min with methionine before being exposed to
MeHg or the MeHg–Cys complex. All reagents were dissolved in
Krebs–Ringer buffer.
Mitochondrial preparation. Liver mitochondria were isolated as
previously described by Brustovetsky and Dubinsky (2000a,
2000b), with some modiﬁcations. After treatment, the liver slices
were washed three times and manually homogenized in cold
buffer I (manitol 225 mM, sucrose 75 mM, K+ EGTA 1 mM, bovine
serum albumin (BSA) 0.1% and K+-HEPES 10 mM pH 7.2), using a
potter glass (length: 10 cm; diameter: 1 cm). Next, the homoge-
nized slices were centrifuged at 2000×g for 7 min at 4 °C. The
pellet was discarded and the supernatant was centrifuged again at
12,000×g for 10 min at 4 °C. Then, the resultant supernatant was
discarded, and the pellet was re-suspended in buffer II (manitol
225 mM, sucrose 75 mM, K+ EGTA 1 mM and K+-HEPES 10 mM
pH 7.2) and re-centrifuged at 12,000×g for 10 min at 4 °C. Finally,
the last supernatant was discarded, and the pellet was re-
suspended and maintained in buffer III (sucrose 100 mM, KCl
65 mM, K+-HEPES 10 mM and EGTA 50 μM pH 7.2) for subsequent
analyses.
Mercury quantiﬁcation. Both the aliquot of the homogenate of liver
slices and themitochondrial suspension isolated from liver sliceswere
subjected to Hg analysis, which was carried out by Cold Vapor-Atomic
Fluorescence Spectrometry according to the method described by
Bergdahl et al., 1998. The total Hg content was determined after acid
digestion with HNO3, H2O2, H2SO4 and perchloric acid (Bergdahl et al.,
1998).
Evaluation of Reactive Species (RS) formationwithDCH(dichloroﬂuorescein-
reactive species, DCH-RS). RS levels were measured using the oxidant
sensing ﬂuorescent probe, 2′,7′-dichloroﬂuorescein diacetate (DCHF–
DA) (Hempel et al., 1999). The oxidation (DCHF–DA) to ﬂuorescent
dichloroﬂuorescein (DCF) was determined at 488 nm for excitation
and 525 nm for emission. After being exposed to the reagents, the
liver slices were homogenized in buffer I (1 mL), and an aliquot of
10 μL (50 μg/protein, Peterson, 1977) of both the homogenate of the
Table 1
Effects of MeHg or MeHg–Cys complex exposure on respiratory rates of rat liver slices.
Rate 1 Rate 2 Rate 3
Respiration
of slices
(nmol O2/mL/min)
Respiration
with succ.
(nmol O2/mL/min)
Respiration with
MeHg or MeHg–Cys
(nmol O2/mL/min)
Control 2.27±0.22 6.59±0.37 5.32±0.47
MeHg 2.26±0.47 6.09±0.32 3.49±0.52a,b
MeHg–Cys 2.10±0.38 5.97±0.18 2.34±0.05a,b,c
With methionine
Control 2.42±0.27 6.17±0.98 5.57±0.75
MeHg 2.38±0.10 6.55±0.53 5.45±0.35d
MeHg–Cys 2.37±0.18 6.10±0.34 3.43±0.26a,b,d
Slices were pre-treated for 15 min with Met (250 μM) and after exposed for 30 min to
MeHg (25 μM) or MeHg–Cys complex (25 μM each).
a Indicates pb0.05, rate 3 compared to 2.
b Indicates pb0.05 from control.
c Indicates pb0.05 from MeHg.
d Indicates pb0.05 from MeHg–Cys complex, n=5 mean±S.E).
Fig. 1. Effects of Met pre-treatment on Hg uptake in rat liver slices (A) andmitochondria
(B) exposed to MeHg or the MeHg–Cys complex. Slices were pre-treated for 15 min
with Met (250 μM) and then exposed for 30 min to MeHg (25 μM) or the MeHg–Cys
complex (25 μM each); (⁎Indicates pb0.05 from control; +Indicates pb0.05 from
MeHg; #Indicates pb0.05 from the MeHg–Cys complex; n=6 mean±S.E.).
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added to 3 mL of buffer III (containing 5 mM glutamate and 5 mM
succinate). After 10 s, 10 μM (DCHF–DA) (prepared in ethanol) was
added to the mixture; and the ﬂuorescence intensity from DCF was
measured for 300 s and expressed as a percentage of the untreated
control group.
Oxygen consumption of liver slices. The oxygen consumption of the
liver slices was measured using an oxymeter (Hansatech model with a
Clark-typeelectrode) at 30 °C. Two slices,weighting approximately 30 μg
(30±2 μg) each, were selected and placed in 2 mL Krebs–Ringer buffer.
Fifteen minutes after methionine addition, glutamate/succinate (5 mM
each) was placed in the medium to increase the respiratory state. After
30 min, either theMeHg solutionor theMeHg–Cys complex solutionwas
added. The respiratory ratio and oxygen consumption were determined
and compared among groups.
Cell viability/mitochondrial activity. Cell viability and mitochondrial
activity were measured by dehydrogenase activity using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) re-
duction assay (Mosmann, 1983). After 30, 60 and 120 min of exposure
to the respective treatment, four liver slices were selected and
incubatedwithMTT (5 μg/mL) for 20 min. TheMTT reduction reaction
was stopped by the addition of 1.5 mL of dimethylsulfoxide (DMSO).
The formazan color and the colorimetric intensity were determined
by the difference in absorbance readings at 570–630 nm, using an UV
2450 Shimadzu spectrophotometer. The ratio values were standard-
ized to protein content and expressed as a percentage of the untreated
control group.
Protein determination. All experiments were standardized to pro-
tein concentrations (Peterson, 1977), and, when appropriate, were
expressed as a percentage of untreated control values.
Statistical analysis. Data were analyzed statistically by one-way
ANOVA, followed by Duncan's multiple range tests when appropriate.
The signiﬁcance between the respiratory rates (Table 1) was analyzed
statistically by t-test. Differences between groups were considered to
be signiﬁcant when Pb0.05.
Results
Hg levels in liver slices and mitochondria isolated from liver slices
The ﬁrst set of experiments was designated to analyze the Hg
content in liver slices and mitochondria isolated from liver slices.The Fig. 1 shows that treatment with MeHg alone caused a
signiﬁcant increase in the Hg concentration in both liver slices (A)
and in mitochondria isolated from liver slices (B) and that the
content of Hg was further increased in the group exposed to the
MeHg–Cys complex when compared to the group treated with
MeHg alone (Figs. 1A and B). The data in Fig. 1 also reveal that
pre-treatment with Met was effective in reducing the Hg levels of
the slices exposed to MeHg or the MeHg–Cys complex (Fig. 1A).
However, in mitochondria isolated from these liver slices, the Met
pre-treatment effect was observed only in the MeHg–Cys complex
group (Fig. 1B).DFC-RS (Diﬂouroscein-Reactive Species) formation
The second set of experiments was performed to analyze the effect
of Met treatment on RS production caused by MeHg in liver slices and
mitochondria isolated from liver slices. Fig. 2 illustrates the levels of
DFC-RS production in liver slices (A) and mitochondria isolated from
liver slices (B) after 45 min of exposure to Met (50–250 μM). The data
show that Met pre-treatment, at all concentrations tested, did not
cause any effect on DFC-RS production when compared to control
values (Figs. 2A and B).
Fig. 3 shows the effects of exposure to MeHg or the MeHg–Cys
complex on DFC-RS generation in liver slices (A) and mitochondria
isolated from liver slices (B). In liver slices, the levels of DFC-RS
production were slightly enhanced by exposure to MeHg or the
MeHg–Cys complex. However, this difference was not statistically
signiﬁcant (Fig. 3A). In contrast, in the mitochondria isolated from
these liver slices, MeHg exposure produced a signiﬁcant increase
on DFC-RS production when compared to levels found in the
control group (Fig. 3B). Furthermore, the DFC-RS production levels
were signiﬁcantly higher in the mitochondria isolated from liver
slices that were treated with the MeHg–Cys complex, when
compared to mitochondria isolated from slices exposed to MeHg
alone (Fig. 3B). Notably, Met pre-treatment was effective in
reducing DFC-RS production only in the mitochondria isolated
from slices treated with the MeHg–Cys complex (Fig. 4).
Fig. 2. Effects of Met pre-treatment on DFC-RS production in rat liver slices (A) andmitochondria (B). Slices were pre-treated for 45 min with Met (50, 100 and 250 μM). The tracings
of ﬁgure are representative lines of 3 independent experiments.
Fig. 3. Effects of exposure to MeHg or the MeHg–Cys complex on DFC-RS production in rat liver slices (A) and mitochondria (B). Slices were exposed for 30 min to MeHg (25 μM) or
the MeHg–Cys complex (25 μM each). (⁎Indicates pb0.05 from control; +Indicates pb0.05 from MeHg; n=5 mean±S.E.). The tracings of Figs. 3A and B are representative and
averaged lines respectively.
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Fig. 5. Effects of exposure to MeHg or the MeHg–Cys complex on oxygen consumption
in rat liver slices (A). Effects of Met pre-treatment on oxygen consumption in rat liver
slices (B) exposed to MeHg or the MeHg–Cys complex. Slices were pre-treated for
15 minwithMet (250 μM) and then exposed for 30 min toMeHg (25 μM) or theMeHg–
Cys complex (25 μM each); (n=5 mean±S.E.).
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The third set of experiments was designed to verify mitochondrial
viability by determining the oxygen consumption by the liver slices.
Fig. 5A shows that MeHg exposure signiﬁcantly decreased the oxygen
consumption of liver slices as compared to the control group, and that
this effect was more pronounced in the liver slices treated with the
MeHg–Cys complex. Interestingly, Met pre-treatment effectively
prevented the reduction of oxygen consumption in both slices treated
with MeHg and slices treated with the MeHg–Cys complex (Fig. 5B)
when compared to control slices (Fig. 5A). A synopsis of MeHg,
MeHg–Cys and Met modulation of mitochondria respiration is
depicted in Table 1.
Cell viability/mitochondrial activity
The ﬁnal set of experiments was performed to evaluate the cell
viability/mitochondria activity in liver slices. Fig. 6 shows that
treatment with MeHg alone caused a signiﬁcant decrease in
mitochondrial activity at all tested times (30, 60 and 120 min.
Figs. 6A, B and C, respectively) when compared to the control
group. At 30 and 60 min, the loss of mitochondrial activity was higher
in liver slices exposed to the MeHg–Cys complex when compared to
those treated only with MeHg (Figs. 6A and B, respectively). At all
times tested, Met pre-treatment prevented mitochondrial dysfunc-
tion induced by both MeHg and MeHg–Cys complex exposure
(Figs. 6A, B and C).
Discussion
It has been postulated that MeHg is transported as a MeHg–Cys
complex by the ubiquitous L-type large neutral amino acid
transporters (LATs) and that transport of this conjugate represents
the main pathway through which MeHg exerts its toxicity in many
tissues (Kerper et al., 1992; Kajiwara et al., 1996; Simmons-Willis
et al., 2002; Adachi 2006; Yin et al., 2008). Corroborating this
hypothesis, our group recently reported that mice chronically
treated with the MeHg–Cys complex show enhanced Hg uptake,
especially in the liver, when compared to other organs, such as
the brain and kidney (Roos et al., 2010). These results are most
likely due to the fact that the liver is a central organ of protein
metabolism and receives amino acids absorbed at the intestinal
levels as well as those derived from other organs and systems
(Duarte, 2003). Although hepatic cells contain some of the same
carriers that have been implicated in the transport of Hg in other
organs, the precise mechanisms underlying the MeHg uptake
across the membrane into normal hepatocytes as well as the
inﬂuence of the MeHg–Cys complex on Hg uptake and hepatoxi-Fig. 4. Effects of Met pre-treatment on DFC-RS production in mitochondria exposed to MeHg
then exposed for 30 min to MeHg (25 μM) or the MeHg–Cys complex (25 μM each). Insets in
from MeHg; #Indicates pb0.05 from MeHg–Cys complex; n=6 mean±S.E.). The tracings ocity have not previously been well deﬁned. Consequently, our
study was primarily designed to investigate the Hg content in
hepatic cells, at both cytosolic and mitochondrial levels after
exposure to MeHg or the MeHg–Cys complex. Several previous
studies have investigated and reported on the toxicology of MeHg,
but, to date, only chelating agents have been employed to
facilitate the removal of Hg from the body (Pingree et al., 2001;
Carvalho et al., 2007). However, these drugs are of limited use
because of their adverse side effects. In the present study, we have
tested the possible use of Met as an efﬁcacious agent capable of
protecting against the deleterious effects of MeHg. We observed
that the Hg concentration in liver slices and in the mitochondria
isolated from liver slices was higher after exposure to the MeHg–
Cys complex (Fig. 1).or the MeHg–Cys complex. Slices were pre-treated for 15 min with Met (250 μM) and
Fig. 4 represent statistical analysis. (⁎Indicates pb0.05 from control; +Indicates pb0.05
f Fig. 4 are representative lines.
Fig. 6. Effects of Met pre-treatment on mitochondrial function of cells exposed to MeHg
or the MeHg–Cys complex. Slices were pre-treated for 15 min with Met (250 μM) and
then exposed for 30, 60 or 120 min to MeHg (25 μM) or the MeHg–Cys complex (25 μM
each) (Figs. 6A, B, and C respectively). (⁎Indicates pb0.05 from control; +Indicates
pb0.05 from MeHg; #Indicates pb0.05 from MeHg–Cys complex; n=6 mean±S.E).
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liver slices (Fig. 1). These results are different from those
reported by Adachi (2006) after exposure of mice to MeHg.
Adachi reported that Met can increase the hepatic deposition of
Hg 2 h after intravenously administration of MeHg and/or
methionine. Since we have used only a single time-point of
exposure of liver slices to MeHg (30 min) and/or Met (45 min),
we cannot disregard the possibility that uptake of MeHg could
be increased in the presence of Met. Alternatively, the decrease
in Hg uptake in the slices by Met may be, at least in part,
related to the relatively high concentration of Met in the
medium and, consequently, to direct interaction between MeHg
and Met, thus lowering the effective free concentration of MeHg.
Accordingly, we can posit that the effect observed in the
presence of Met may be related to a direct interaction of the
sulfur atom and/or amino end of Met with MeHg (Rabenstein
and Fairhurst 1975). Alternatively, Met may be reducing the
uptake of MeHg complexed with endogenous cysteine in liver
slices. In addition, here we have worked with an in vitro system
derived from rats. It is feasible that results obtained after in vivo
exposure may be modiﬁed by changes in the amino acids and/or
MeHg–Cys complex distribution and metabolism in other animal
species.
Thus, our results corroborate that (1) the MeHg–Cys complex
is a substrate for the neutral amino acid carrier L-type in the
liver and (2) Met prevents the hepatoxicity induced by MeHg,
reﬂecting its ability to reduce MeHg uptake as well as
cytotoxicity in liver slices and mitochondria isolated from liverslices treated with the MeHg–Cys complex. Regarding the
mechanisms which underlie the MeHg-mediated hepatoxicity,
we found that exposure to MeHg or the MeHg–Cys complex
increased DFC-RS formation, particularly in mitochondria isolated
from liver slices. These results are consistent with previous
reports from our group, which have shown that MeHg increases
ROS production in cortical brain slices only at high concentra-
tions (100 μM) and after long-term exposure (2 h) (Roos et al.,
2009; Wagner et al., 2010). These data also suggest that
mitochondria are more sensitive to low MeHg concentrations.
In agreement with the present data, it has been previously
reported that MeHg, at a concentration of 5 μM, increases ROS
levels in mitochondria isolated from rat brain slices (Dreiem and
Seegal, 2007; Wagner et al., 2010,). It is noteworthy that in our
experimental protocol, MeHg and/or the MeHg–Cys complex
reduced mitochondrial activity. These effects are likely related,
since ROS can react rapidly with cellular macromolecules and
induce mitochondrial damage (Puntel et al., 2010; Colquhoun,
2010; Forkink et al., 2010). Furthermore, because MeHg can
cause a pronounced disruption of calcium homeostasis (Stavrovs-
kaya and Kristal, 2010), it is plausible that alterations in Ca2+
homeostasis could lead to the collapse of the inner mitochondrial
membrane potential, as well as the opening of the mitochondrial
permeability pore, events that ultimately result in the loss of
mitochondrial function, ROS formation and cell death (Puntel et al.,
2010; Colquhoun, 2010; Forkink et al., 2010). Thus, it is reasonable
to assume that mitochondria are the primary molecular target for
MeHg- and MeHg–Cys-induced cytotoxicity. In addition, we assessed
mitochondrial function by analyzing the oxygen consumption of
liver slices treatedwithMeHgor theMeHg–Cys complex.Weobserved
that MeHg exposure attenuated mitochondrial respiration and
that this effect was greater in the slices treated with the MeHg–Cys
complex. This is in agreement with a recent study, which has dem-
onstrated that dietary MeHg causes a signiﬁcant decrease in both
state 3 of mitochondrial respiration and cytochrome c oxidase activity
in mitochondria from contaminated zebraﬁsh muscle ﬁbers (Cambier
et al., 2009); and inhibits the activity of the mitochondrial complexes
II–III, IV, as well as mitochondrial creatine kinase (Glaser et al., 2010).
Furthermore, this work has shown that MeHg exposure induces a
decoupling of mitochondrial oxidative phosphorylation in the skeletal
muscles of the zebraﬁsh (Cambier et al., 2009).
Interestingly, we observed the ability of Met to afford
protection against the deleterious effects of MeHg and/or the
MeHg–Cys complex. In fact, Met decreased DFC-RS production and
prevented the inhibition of mitochondrial respiration and cell
viability induced by exposure to MeHg and/or the MeHg–Cys
complex. These data show, for the ﬁrst time, Met's effectiveness in
both reducing the bioavailability of MeHg in hepatocytes, as well
as its modulation of mitochondrial function. In terms of molecular
mechanisms, it is reasonable to assume that the protective effects
of Met are linked to its structural similarities with the MeHg–Cys
complex. This idea is in agreement with the existence of a
mitochondrial neutral amino acid transport (Raymond et al.,
1977), which is likely responsible for the uptake of MeHg (as
MeHg–Cys complex) into mitochondria. Based on our results, it is
possible to state that LAT is not only important for the transport
of MeHg into the cell, but also for the transport of MeHg within
cellular organelles, allowing for the occurrence of mitochondrial
toxicity probably due to the direct effects of MeHg in mitochon-
drial proteins.
In summary, the results obtained in this study demonstrate
that Met prevents the toxic effects of MeHg and the MeHg–Cys
conjugate on mitochondrial function and cell viability. Further-
more, the results suggest the possible use of this amino acid as a
therapeutic agent for treating acute MeHg exposure. Additional
studies to determine the efﬁcacy of Met in reducing the
34 D.H. Roos et al. / Toxicology and Applied Pharmacology 252 (2011) 28–35gastrointestinal absorption of MeHg as well as its ability to
accelerate MeHg excretion in animal models of MeHg exposure are
well warranted.
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